Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQB2928 + almonertinib
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TQB2928 + almonertinib is an investigational combination therapy under clinical evaluation for the treatment of advanced non-small cell lung cancer (NSCLC). Almonertinib (also known as HS-10296, brand name Ameile, and aumolertinib) is an orally available, third-generation small molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. It selectively targets EGFR-sensitizing mutations and the T790M resistance mutation, which are common in NSCLC. Almonertinib irreversibly inhibits mutant EGFR signaling pathways involved in tumor cell proliferation and survival[2][7][8]. TQB2928's mechanism of action has not been explicitly described in the provided sources; it is being studied in combination with almonertinib for potential synergistic effects against advanced NSCLC[1].
- Brand names
- Ameile
- Other names
- aumolertinib
02
Targets
Beyond the preview
Go deeper on TQB2928 + almonertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQB2928 + almonertinib.